Pay in 4 interest-free payments of $6.73 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Where AOD-9604 Fits in Clinical Practice In physician-supervised practice, AOD-9604 has typically been considered for: Fat loss adjunct alongside lifestyle intervention [Body composition optimization]( in patients already pursuing multiple strategies GH-like lipolytic effects in patients where full GH axis intervention is undesirable Combined protocols alongside other peptides It is not positioned as a primary weight loss therapy GLP-1 class compounds have substantially more evidence and larger effect sizes
Wrapp, D
Khavinson VKh, Bondarev IE, Butyugov AA, Smirnova TD
Journal of Cosmetic Science , 60(4), 377385
The FDA classified Epitalon as a Category 2 bulk drug substance under Section 503A guidance in September 2023, confirmed in September 2024
[DOI] [PubMed] [Google Scholar] 27.Hall M.N., Niedzwiecki M., Liu X., Harper K.N., Alam S., Slavkovich V., Ilievski V., Levy D., Siddique A.B., Parvez F., et al
US$ 28.69
US$ 22.24
US$ 20.07
US$ 22.94
